A retrospective study over 4.5 years in 35 patients with high-need plaque psoriasis evaluated the efficacy and safety of etanercept as a sequential treatment in patients previously treated with efalizumab. These high-need patients required a switch due to loss of efficacy, nonresponse, rebound or commercial withdrawal of efalizumab in Europe. Nonresponse was defined as not achieving a 50% reduction in the Psoriasis Area and Severity Index (PASI 50) in 6 months and rebound was defined as attaining a PASI of > 125% of baseline values or development of new lesions within 8 weeks from efalizumab discontinuation. All 35 patients received etanercept for at least 24 weeks. At 24 weeks, 57% of ...